A Systems-Based Approach to Chronic Pain in Women’s Health

April 14, 2026

Chronic pain conditions in women’s health, such as adenomyosis, endometriosis, and fibromyalgia, are often approached as distinct diagnoses. However, some emerging clinical perspectives suggest that chronic pain in women’s health may be better understood as part of a broader, interconnected network of dysregulated systems rather than isolated disease states.

For many patients, chronic pain reflects overlapping physiological stressors involving immune, endocrine, and neurologic pathways. Recognizing these connections can support more comprehensive, individualized treatment strategies, particularly for patients who are sensitive to standard therapies or require tailored dosing.

Connecting the Dots: Mast Cell Activation, Dysautonomia, and Hypermobility

A growing body of literature highlights the role of mast cell activation disorders (MCAD), including mast cell activation syndrome (MCAS) and systemic mastocytosis, in chronic pain and inflammatory conditions. Mast cells play a central role in immune signaling, releasing mediators such as histamine, cytokines, and prostaglandins that can influence pain perception, vascular tone, and tissue inflammation.

These conditions are increasingly recognized alongside:

Dysautonomia, including postural orthostatic tachycardia syndrome (POTS)
Hypermobility spectrum disorders, such as Ehlers-Danlos syndrome (EDS)

This triad, mast cell activation, autonomic dysfunction, and connective tissue disorders, has been proposed in some literature and clinical observations. And can contribute to widespread, multisystem symptoms, including:

Chronic pelvic pain
Fatigue and cognitive dysfunction
Gastrointestinal disturbances
Heightened medication sensitivities

For clinicians, this reinforces the importance of evaluating patients through a systems-based lens, rather than focusing solely on individual diagnoses.

Inflammation as a Contributing Driver of Chronic Pain in Women's Health

Inflammation is not simply a downstream effect in these conditions; may act as a contributing driver in some patients.

In both chronic pain and autoimmune presentations, inflammatory signaling pathways can be influenced by a range of factors, including:

Diet and metabolic health
Microbial imbalances and potential alterations in gut permeability
Environmental exposures
Chronic stress and trauma

This concept extends to autoinflammatory and autoimmune disorders, where dysregulated immune responses contribute to persistent symptoms and disease progression.

Therapeutic Considerations: Individualization Matters

Given the complexity of these overlapping conditions, treatment often requires a high degree of personalization. Standard, one-size-fits-all therapies may not be appropriate for patients with:

Medication sensitivities or excipient intolerances
Mast cell reactivity
Complex comorbidities

In these cases, clinicians may consider a range of therapeutic tools, including:

Low-Dose Naltrexone (LDN)

LDN has been explored for its potential to modulate immune function and reduce neuroinflammation. Proposed mechanisms include:

Transient opioid receptor blockade leading to endorphin upregulation
Modulation of microglial activation
Downregulation of pro-inflammatory cytokines

LDN has been studied in conditions such as fibromyalgia, autoimmune disorders, and chronic pain syndromes, though patient selection and dosing strategies remain critical.

Bioidentical Hormone Therapy (bHRT)

Hormonal fluctuations can significantly influence inflammatory pathways, pain perception, and immune function.

During transitions such as perimenopause and menopause, patients may experience:

Increased inflammatory burden
Metabolic dysfunction
Changes in HPA axis regulation and circadian rhythm

Individualized hormone therapy may be considered in appropriate patients, particularly when standard formulations are not well tolerated or when precise dosing is required.

Mast Cell Stabilization and Targeted Support

Agents such as ketotifen and other mast cell stabilizers may be utilized in select patients to help manage mediator release and reduce symptom burden.

Additionally, emerging interest in oral peptides reflects ongoing exploration into targeted signaling pathways, though clinical use should be guided by careful evaluation and evidence-based consideration.

The Role of the Gut, Mitochondria, and Systemic Regulation

Chronic inflammation may be linked to broader systemic dysfunction, including:

Gut microbiome imbalance and intestinal hyperpermeability
Mitochondrial dysfunction and impaired energy production
Thyroid and metabolic dysregulation
Circadian rhythm disruption and HPA axis imbalance

These factors can contribute to symptom persistence and may influence therapeutic outcomes, reinforcing the need for a multifactorial approach to care.

Why Compounding Plays a Critical Role

For patients with complex, overlapping conditions, individualized therapy is often not optional; it can be valuable in cases where commercially available options do not meet specific patient needs.

Compounding pharmacies support this approach by enabling:

Customized dosing strategies tailored to patient response
Alternative dosage forms for improved tolerability
Exclusion of non-essential excipients that may trigger sensitivities
Combination therapies designed to simplify regimens

This level of precision can be particularly valuable in populations with heightened reactivity, where standard commercial products may not meet clinical needs.

Conclusion

Chronic pain in women’s health is increasingly understood as part of a broader network of immune, endocrine, and neurologic interactions. Conditions such as endometriosis, fibromyalgia, and adenomyosis may share underlying mechanisms involving inflammation, mast cell activation, and systemic dysregulation.

For clinicians, this shift in perspective highlights the importance of:

Looking beyond isolated diagnoses
Considering interconnected physiological systems
Utilizing individualized, patient-centered therapeutic strategies

As the science continues to evolve, collaborative care models, including the use of compounded medications, can help support more tailored and responsive treatment approaches for complex patients.